C1orf106, an innate immunity activator, is amplified in breast cancer and is required for basal-like/luminal progenitor fate decision

Science China. Life Sciences
Ji MaHongquan Zhang

Abstract

Basal-like breast cancer with a luminal progenitor gene expression profile is an aggressive subtype of breast cancer with a poorer prognosis compared with other subtypes. However, genes that specifically promote basal-like breast cancer development remain largely unknown. Here, we report that a novel gene C1orf106 plays an important role in maintaining the feature of basal-like/luminal progenitors. C1orf106 is frequently amplified and overexpressed in basal-like breast cancer and is associated with a poor outcome in patients. In human TCGA database, C1orf106 expression was correlated with upregulation of ELF5 and downregulation of GATA3, two transcription factors that regulate mammary gland stem cell fate. Enhanced expression of C1orf106 promotes tumor progression and expression of basal-like/luminal progenitor marker ELF5; depletion of C1orf106 suppresses tumorigenesis and expression of basal-like/luminal progenitor marker GATA3. These findings suggest that C1orf106 maintains the basal-like/luminal progenitor character through balancing the expression of ELF5 and GATA3. Taken together, we demonstrated that C1orf106 is an important regulator for basal-like/luminal progenitors and targeting C1orf106 is of therapeutic value for b...Continue Reading

References

Aug 30, 2000·Nature·C M PerouD Botstein
Dec 26, 2006·Nature Cell Biology·Marie-Liesse Asselin-LabatJane E Visvader
Dec 18, 2007·American Journal of Surgery·Chukwuemeka U IhemelanduWayne A Frederick
Aug 8, 2009·Nature Medicine·Aleix Prat, Charles M Perou
Oct 17, 2009·Genes & Development·Daisuke YamajiLothar Hennighausen
Sep 4, 2010·Breast Cancer Research : BCR·Aleix PratCharles M Perou
Jul 23, 2011·Breast Disease·Cynthia X MaMatthew J Ellis
Mar 6, 2012·Cell·Wenjun GuoRobert A Weinberg
Jan 28, 2014·Nature·Anne C RiosJane E Visvader
Jun 3, 2014·Surgical Oncology Clinics of North America·Prasanna Alluri, Lisa A Newman
Oct 19, 2016·Nature Reviews. Clinical Oncology·Giampaolo BianchiniLuca Gianni
Jan 8, 2017·Cold Spring Harbor Perspectives in Medicine·Mei ZhangJeffrey M Rosen
Apr 25, 2017·The Journal of Clinical Investigation·Jie YanClara Abraham
May 24, 2017·Science China. Life Sciences·Xiaohui ZhangDali Li
Oct 19, 2017·Science China. Life Sciences·Xu LiJunjie Chen
Feb 6, 2018·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Fumiya OmataHironobu Sasano
Nov 22, 2018·Science China. Life Sciences·Bing LiHongquan Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.